H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation ...

Fintel reports that on January 2, 2025, HC Wainwright & Co. initiated coverage of Corvus Pharmaceuticals (NasdaqGM:CRVS) with ...

H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target Corvus is a clinical-stage ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has earned a consensus recommendation of “Buy” from the four ...

Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical compan Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT ...

Analysts at HC Wainwright initiated coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) in a note issued to investors on Thursday,Briefing.com Automated Import reports. The ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...

Investing.com -- Corvus Pharmaceuticals, Inc. (NASDAQ: NASDAQ:CRVS) stock fell 34% following the interim results from its Phase 1 trial of soquelitinib for treating moderate to... ByInvesting.com ...